Patients with HER2-negative LR/mBC who had received no prior chemotherapy for advanced disease were randomised to either BEV-PAC ( bevacizumab 10 mg kg ( -1 ) days 1 and 15 plus paclitaxel 90 mg m ( -2 ) days 1 , 8 and 15 q4w ) or BEV-CAP ( bevacizumab 15 mg kg ( -1 ) day 1 plus capecitabine 1000 mg m ( -2 ) bid days 1-14 q3w ) .